Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder

References

• Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832–840.
   PubMed Web of Science ®Google Scholar
• Riemann D, Nissen C, Palagini L, et al. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015;14(5):547–558.
   PubMed Web of Science ®Google Scholar
• Brenner P, Piehl F. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurol Scand. 2016;134(Suppl 200):47–54.
   PubMed Web of Science ®Google Scholar
• Penner I-K, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017;13(11):662–675.
   PubMed Web of Science ®Google Scholar
• Mohandas H, Jaganathan SK, Mani MP, et al. Cancer-related fatigue treatment: an overview. J Cancer Res Ther. 2017;13(6):916–929.
   PubMed Web of Science ®Google Scholar
• Zielinski MR, Systrom DM, Rose NRF. Sleep, and autoimmune and related disorders. Front Immunol. 2019;10:1827.
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien IL: American Academy of Sleep Medicine; 2014.
   Google Scholar
• Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349.
   PubMed Web of Science ®Google Scholar
• Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care. 2009;15(Suppl):S6–13.
   PubMed Web of Science ®Google Scholar
• Wu JQ, Appleman ER, Salazar RD, et al. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med. 2015;175(9):1461–1472.
   PubMed Web of Science ®Google Scholar
• Lichstein KL, Means MK, Noe SL, et al. Fatigue and sleep disorders. Behav Res Ther. 1997;35(8):733–740.
   PubMed Web of Science ®Google Scholar
• Riedel BW, Lichstein KL. Insomnia and daytime functioning. Sleep Med Rev. 2000;4(3):277–298.
   PubMed Web of Science ®Google Scholar
• Ji X, Ivers H, Savard J, et al. Residual symptoms after natural remission of insomnia: associations with relapse over 4 years. Sleep. 2019;42(8):zsz122.
   Web of Science ®Google Scholar
• Lyw H, Ssm N. Non-pharmacological interventions for fatigue in older adults: a systematic review and meta-analysis. Age Ageing. 2020;49(3):341–351.
   PubMed Web of Science ®Google Scholar
• Mücke M, Mochamat CH, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016;7(1):23–27.
   PubMed Web of Science ®Google Scholar
• Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry. 2004;161(11):2126–2128.
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61(2):162–176.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Q, Ji B, et al. The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220.
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150–155.
   PubMed Web of Science ®Google Scholar
• Sun Y, Tisdale RK, Kilduff TS. Hypocretin/orexin receptor pharmacology and sleep phases. Front Neurol Neurosci. 2021;45:22–37.
   PubMedGoogle Scholar
• Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs. Pharmacol Rep. 2016;68(2):231–242.
   PubMed Web of Science ®Google Scholar
• Roecker AJ, Cox CD, Coleman PJ. Orexin receptor antagonists: new therapeutic agents for the treatment of Insomnia. J Med Chem. 2016;59(2):504–530.
   PubMed Web of Science ®Google Scholar
• Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171(2):283–293.
   PubMed Web of Science ®Google Scholar
• Beuckmann CT, Suzuki M, Ueno T, et al. In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362(2):287–295.
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA network open. 2019;2(12):e1918254.
   PubMed Web of Science ®Google Scholar
• Kärppä M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE-2. Sleep. 2020;43(9):zsaa123.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
   Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–1123.
   PubMed Web of Science ®Google Scholar
• Valko PO, Bassetti CL, Bloch KE, et al. Validation of the fatigue severity scale in a Swiss cohort. Sleep. 2008;31(11):1601–1607.
   PubMed Web of Science ®Google Scholar
• Rosti-Otajarvi E, Hamalainen P, Wiksten A, et al. Validity and reliability of the fatigue severity scale in Finnish multiple sclerosis patients. Brain Behav. 2017;7(7):e00743.
   PubMed Web of Science ®Google Scholar
• Goligher EC, Pouchot J, Brant R, et al. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol. 2008;35(4):635–642.
   PubMed Web of Science ®Google Scholar
• Nordin Å, Taft C, Lundgren-Nilsson Å, et al. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16(1):62.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Kherani RB, Brant R, et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol. 2008;61(7):705–713.
   PubMed Web of Science ®Google Scholar
• Robinson D Jr., Zhao N, Gathany T, et al. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial. Curr Med Res Opin. 2009;25(5):1121–1130.
   PubMed Web of Science ®Google Scholar
• Rooney S, McFadyen DA, Wood DL, et al. Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disord. 2019;35:158–163.
   PubMed Web of Science ®Google Scholar
• Sobreira M, Almeida MP, Gomes A, et al. Minimal clinically important differences for measures of pain, lung function, fatigue, and functionality in spinal cord injury. Phys Ther. 2021;101(2):pzaa210.
   PubMed Web of Science ®Google Scholar
• Erol K, Ş K E, Ertaş R. Fatigue is common and predicted by female gender and sleep disturbance in patients with chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2021;9(1):469-476.
   PubMed Web of Science ®Google Scholar
• Merkies IS, Schmitz PI, Samijn JP, et al. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53(8):1648–1654.
   PubMed Web of Science ®Google Scholar
• Ongre SO, Dalen I, Tysnes OB, et al. Progression of fatigue in Parkinson’s disease - a 9-year follow-up. Eur J Neurol. 2021;28(1):108–116.
   PubMed Web of Science ®Google Scholar
• Pettersson S, Boström C, Eriksson K, et al. Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. Lupus. 2015;24(9):955–965.
   PubMed Web of Science ®Google Scholar
• Schreiner P, Rossel JB, Biedermann L, et al. Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther. 2021;53(1):138–149.
   PubMed Web of Science ®Google Scholar
• Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017–1024.
   PubMed Web of Science ®Google Scholar
• Yardley J, Pinner K, Moline M, et al. Impact of lemborexant on insomnia disease severity and fatigue in elderly subjects with insomnia from SUNRISE-2. Am J Geriatr Psychiatry. 2020;28(4):S134–S135.
   Web of Science ®Google Scholar
• Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs. 2008;61(6):664–675.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim S, Jeon S, et al. Factors associated with fatigue in patients with insomnia. J Psychiatr Res. 2019;117:24–30.
   PubMed Web of Science ®Google Scholar
• Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep. 2007;30(11):1547–1554.
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38–48.
   PubMed Web of Science ®Google Scholar
• Pardini M, Capello E, Krueger F, et al. Reward responsiveness and fatigue in multiple sclerosis. Mult Scler. 2013;19(2):233–240.
   PubMed Web of Science ®Google Scholar
• Zare B, Moosavi B, Torabi-Nami M. Wake-Promoting agents; insights into clinical use and molecular perspectives. J Adv Med Sci Appl Technol. 2016;2(1):129–140.
   Google Scholar
• Pucci E, Branas P, D’Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;2007(1):CD002818.
   PubMed Web of Science ®Google Scholar
• Pallais JP, Kotz CM, Stanojlovic M. Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. Neural Regen Res. 2020;15(6):1039–1040.
   PubMed Web of Science ®Google Scholar
• Burfeind KG, Yadav V, Marks DL. Hypothalamic dysfunction and multiple sclerosis: implications for fatigue and weight dysregulation. Curr Neurol Neurosci Rep. 2016;16(11):98.
   PubMed Web of Science ®Google Scholar